RJA
IRON icon

Raymond James & Associates’s Disc Medicine IRON Stock Holding History

Raymond James & Associates’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$288K Buy
5,864
+35
+0.6% +$1.64K ﹤0.01% 3429
2024
Q2 		$263K Sell
5,829
-571
-9% -$19.4K ﹤0.01% 3446
2024
Q1 		$398K Buy
+6,400
New +$415K ﹤0.01% 3203

Other funds holding IRON

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Raymond James & Associates's IRON Position: Q3 2024 in Review

Raymond James & Associates increased its Disc Medicine (IRON) stake by 0.6% in Q3 2024, buying an estimated $1.64K and bringing the position to 5,864 shares worth $288K. The position accounts for ﹤0.01% of the portfolio, ranked #3429.

Raymond James & Associates first reported a position in IRON in Q1 2024 and has held it in 3 quarters since. The position peaked at $398K in Q1 2024. 132 funds tracked by Wall St. Rank hold IRON as of Q3 2024.

  • Raymond James & Associates held 5,864 shares of Disc Medicine worth $288K as of Q3 2024.
  • Raymond James & Associates bought 35 Disc Medicine shares in Q3 2024, an estimated $1.64K.
  • Disc Medicine made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3429 holding.
  • Raymond James & Associates first reported a position in Disc Medicine in Q1 2024 and has held it in 3 quarters since.
  • Raymond James & Associates's Disc Medicine position peaked at $398K in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Disc Medicine as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.